Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported Q3 Syfovre revenues that came in below expectations. The firm ...

Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race ...

Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations.Please watch the video at Investors.com - How To Buy Stocks: Ways ...

Wells Fargo lowered the firm’s price target on Apellis (APLS) to $30 from $43 and keeps an Equal Weight rating on the shares. The firm thinks Q3 was validating for its view of a slowing GA market and ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

UBS analyst Eliana Merle lowered the firm’s price target on Apellis (APLS) to $45 from $74 and keeps a Buy rating on the shares. The firm says the company’s Q3 resent expectatoins. Published first on ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Baird lowered the firm’s price target on Apellis (APLS) to $55 from $92 and keeps an Outperform rating on the shares. The firm said they reported 3Q24 results, including a sequentially lower Syfovre ...

On Friday, Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $27.98 which represents a slight increase of $0.72 or 2.64% from the prior close of $27.26. The stock opened ...